¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽÅÀåÇÐȸ KSN(Korea Society of Nephrology) 2022 (4ÀÏÂ÷) : 2022-05-29

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѽÅÀåÇÐȸ KSN(Korea Society of Nephrology) 2022 (4ÀÏÂ÷) : 2022-05-29
±³À°ÀÏÀÚ : 2022-05-29
±³À°Àå¼Ò : ¼­¿ï µå·¡°ï½ÃƼȣÅÚ  
±³À°ÁÖÁ¦ : KSN(Korea Society of Nephrology) 2022 (4ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
´ã´çÀÚ : ´ëÇѽÅÀåÇÐȸ
¿¬¶ôó : 02-3486-8736  
À̸ÞÀÏ : ksn@ksn.or.kr      
±³À°Á¾·ù : ³»°úÀÇ»çÇÐ
Âü¼®¿¹»óÀοø : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡   (ÀÏ¹Ý 4Á¡ / Çʼö 2Á¡)  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 34 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 200,000¿ø      
ºñ°í ¡áȸ¿ø: »çÀü(100,000)/ÇöÀå(150,000) ¡áºñȸ¿ø: »çÀü(150,000)/ ÇöÀå(200,000) ¡áFellow-in-training,Resident,Trainee,Student,Nurse,etc: »çÀü(50,000)/ ÇöÀå(35,000) *Medical Student: ¸éÁ¦      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-29 Room 1(5F) 08:30~09:00 Dialysis Adequacy Update (Hemo Dialysis /Peritoneal Dialysis Adequacy)  Áø±Ôº¹(°è¸í´ëÇб³ µ¿»êº´¿ø) 
±³À°½Ã°£ 05-29 Room 1(5F) 09:00~09:30 Management of Secondary Hyperparathyroidism in Dialysis Patients: Case Oriented  ÀÌÀ¯È£(ºÐ´çÂ÷º´¿ø) 
±³À°½Ã°£ 05-29 Room 1(5F) 09:30~10:00 30 Incremental, Hybrid, and Extended Dialysis  ±æÈ¿¿í(õ¾È¼øõÇ⺴¿ø) 
±³À°½Ã°£ 05-29 Room 1(5F) 10:00~10:30 Anemia Management in Dialysis Patients: Target Ferritin and Hemoglobin  ±è¼­¸°(¾ç»êºÎ»ê´ëº´¿ø) 
±³À°½Ã°£ 05-29 Room 1(5F) 10:40~11:10 Clinical Implications and Prescriptions of On-Line Hemodiafiltration  ±èÁø¼÷(°æÈñÀÇ´ë) 
±³À°½Ã°£ 05-29 Room 1(5F) 11:10~11:40 Prescription of Automated Peritoneal Dialysis  °­°æÇ¥(ÀüºÏÀÇ´ë) 
±³À°½Ã°£ 05-29 Room 1(5F) 11:40~12:10 Evaluation and Management of Av Access as a Nephrologist  ÀÌÇü¼®(ÇѸ²´ëÇб³¼º½Éº´¿ø) 
±³À°½Ã°£ 05-29 Room 1(5F) 12:10~12:40 Non-infectious Peritoneal Dialysis Complications  ¹Ú°æ¼±(¿ï»ê´ëÇб³º´¿ø) 
±³À°½Ã°£ 05-29 Room 1(5F) 13:30~14:10 ÄáÆϺ´ °øÅë µ¥ÀÌÅÍ ¸ðµ¨ ¿¬±¸È¸ °úÁ¦  ±¸È£¼®(ÀÎÁ¦¹éº´¿ø) 
±³À°½Ã°£ 05-29 Room 1(5F) 14:10~14:50 ½ÅÀåÀ̽ÄȯÀÚ¿¡¼­ °Å´ë¼¼Æ÷¹ÙÀÌ·¯½º ¿¹¹æ¿ä¹ýÀÇ È¿°úºÐ¼® ¿¬±¸  Á¤°æȯ(°æÈñÀÇ´ë) 
±³À°½Ã°£ 05-29 Room 1(5F) 14:50~15:30 Genetic identification of inherited cystic kidney diseases for implementing precision medicine  ¹ÚÇýÀÎ(ÇѸ²´ëÇб³) 
±³À°½Ã°£ 05-29 Room 1(5F) 15:40~16:10 ÀΰøÁö´É(AI) ½Ã´ëÀÇ ÀÇ·á À±¸® ¹®Á¦  ¾ç±¤¸ð(»ï¼º¼­¿ïº´¿ø) 
±³À°½Ã°£ 05-29 Room 1(5F) 16:10~16:40 ÀÇÇÐÀü¹®Á÷¾÷¼º¿¡ ±â¹ÝÇÑ ÀÚÀ²±ÔÁ¦  ¾È´ö¼±(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 05-29 Room 1(5F) 16:40~17:10 ÀÇ·áºÐÀï °¨Á¤ »ç¾È¿¡ ´ëÇÑ ¹ý·üÀû Çؼ®  ±è¿¬Èñ(¹ý¹«¹ýÀÎ ÀǼº) 
±³À°½Ã°£ 05-29 Room 1(5F) 17:10~17:40 Àΰø½ÅÀå½Ç¿¡¼­ÀÇ À±¸®Àû ¹®Á¦  ±è»ó¿í(±¤¸í¼ö³»°ú) 
±³À°½Ã°£ 05-29 Room 2(3F) 08:30~10:30 Education on Kidney Transplantation for Patients Initiating Dialysis  ÀÌÇÏÁ¤(¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 05-29 Room 2(3F) 09:00~09:30 Donor Evaluation and Follow Up in Kidney Transplantation  ±èÁöÀº(°í·ÁÀǴ뱸·Îº´¿ø) 
±³À°½Ã°£ 05-29 Room 2(3F) 09:30~10:00 Recipient Evaluation and Follow Up in Kidney Transplantation  È²Çö¼®(°æÈñÀÇ´ë) 
±³À°½Ã°£ 05-29 Room 2(3F) 10:00~10:30 Management of Patients With a Failed Kidney Transplant  ±èµµÇü(°­³²¼º½Éº´¿ø) 
±³À°½Ã°£ 05-29 Room 2(3F) 10:40~11:10 Artery Disease in End Stage Renal Disease Patients: Central / Peripheral  ±è»ó¹Î(ÃæºÏ´ëº´¿ø) 
±³À°½Ã°£ 05-29 Room 2(3F) 11:10~11:40 Chronic Kidney Disease-Mineral Bone Disorder Management: Fracture Risk Evaluation & Intervention  ÀÌÀåÇÑ(ºÐ´çÁ¦»ýº´¿ø) 
±³À°½Ã°£ 05-29 Room 2(3F) 11:40~12:10 Blood Pressure in Chronic Kidney Disease/End Stage Renal Disease: 2021 Update  ÃÖÇý¹Î(¸íÁö´ëº´¿ø) 
±³À°½Ã°£ 05-29 Room 2(3F) 12:10~12:40 Iron Treatment in Chronic Kidney Disease/End Stage Renal Disease Patients  ¹ÚÀçÀ±(µ¿±¹´ëÀϻ꺴¿ø) 
±³À°½Ã°£ 05-29 Room 2(3F) 13:30~13:54 Global Comparison of Nationwide Renal Registry Data  ¹ÚÁ¾ÇÏ(¿ï»ê´ëÇб³º´¿ø) 
±³À°½Ã°£ 05-29 Room 2(3F) 13:54~14:18 °³¿ø°¡ ÀÔÀå¿¡¼­ ¹Ù¶óº» µî·Ï»ç¾÷  À±Ã¢¿¬(À±¿µ¼® ³»°úÀÇ¿ø) 
±³À°½Ã°£ 05-29 Room 2(3F) 14:18~14:42 2022³â Àΰø½ÅÀå½Ç ÀÎÁõÆò°¡ º¸°í  ÀÌ¿µ±â(°­³²¼º½Éº´¿ø) 
±³À°½Ã°£ 05-29 Room 2(3F) 14:42~15:06 ÀûÁ¤¼º Æò°¡ÀÇ °ú°Å, ÇöÀç, ±×¸®°í ¹Ì·¡  ÀÌÁø¿ë(°Ç°­º¸Çè½É»çÆò°¡¿ø) 
±³À°½Ã°£ 05-29 Room 2(3F) 15:06~15:30 Åõ¼®Àü¹®ÀÇÀÇ ÇöÀç¿Í ¹Ì·¡  È²¿ø¹Î(°Ç¾çÀÇ´ë) 
±³À°½Ã°£ 05-29 Room 2(3F) 15:40~16:10 Application of Novel Anemia Treatment in Chronic Kidney Disease  ±èÁ°æ(ÇѸ²´ëÇб³¼º½Éº´¿ø) 
±³À°½Ã°£ 05-29 Room 2(3F) 16:10~16:40 Recent Advances to Control Hyperphosphatemia  È²ÁøÈ£(Áß¾ÓÀǴ뺴¿ø) 
±³À°½Ã°£ 05-29 Room 2(3F) 16:40~17:10 New Treatment Strategies for Diabetic Nephropathy  ¹Ú¿äÇÑ(°Ç¾çÀÇ´ë) 
±³À°½Ã°£ 05-29 Room 2(3F) 17:10~17:40 Drug Development of IgA Nephropathy and FSGS(Focal Segmental Glomerulosclerosis)  ¹ÚÀçÀ±(µ¿±¹´ëÀϻ꺴¿ø) 
±³À°½Ã°£ 05-29 Room 3(3F) 08:30~09:00 º¹¸·Åõ¼® ´ã´ç °£È£»çÀÇ ¿ªÇÒ (º¹¸·Åõ¼® ÀçÅðü¸®»ç¾÷)  ÀÌ¿µ±â(°­³²¼º½Éº´¿ø) 
±³À°½Ã°£ 05-29 Room 3(3F) 09:00~09:30 Basic Principles of Peritoneal Dialysis  ±èÈ¿Áø(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 05-29 Room 3(3F) 09:30~10:00 Management of Fluid and Electrolyte Disturbances in Peritoneal Dialysis Patients  ±è°æ¹Î(À»ÁöÀǴ뺴¿ø) 
±³À°½Ã°£ 05-29 Room 3(3F) 10:00~10:30 Management of Complications of Peritoneal Dialysis  ±èÇظ®(¼¼Á¾Ãæ³²´ëÇб³º´¿ø) 
±³À°½Ã°£ 05-29 Room 3(3F) 10:40~11:10 Dialysis Water Quality Control  ¹Ú»ï¿¤(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 05-29 Room 3(3F) 11:10~11:40 Nutritonal Support in Hemo Dialysis Patients  ±èÇü¿Ï(ÀüºÏ´ëÇб³º´¿ø) 
±³À°½Ã°£ 05-29 Room 3(3F) 11:40~12:10 Management of Chronic Kidney Disease-Mineral Bone Disorder  Â÷ÁøÁÖ(°í·Á´ëÇб³¾È»êº´¿ø) 
±³À°½Ã°£ 05-29 Room 3(3F) 12:10~12:40 Management of Osteoporosis in Hemo Dialysis Patients  ÀÌÇö½Â(Ãæ³²´ëÇб³º´¿ø) 
±³À°½Ã°£ 05-29 Room 3(3F) 13:30~14:00 Arteriovenous Fistula Doppler Ultrasonogram and Access Surveillance  ±èÇü¿ì(¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 05-29 Room 3(3F) 14:00~14:30 Ultrasonogram for Nephrologists  ±è⼺(Àü³²´ëÇб³º´¿ø) 
±³À°½Ã°£ 05-29 Room 3(3F) 14:30~15:00 Intensive Care Nephrology  ÀÌÁ¤È¯(¼­¿ïƯº°½Ãº¸¶ó¸Åº´¿ø) 
±³À°½Ã°£ 05-29 Room 3(3F) 15:00~15:30 About Onco-nephrology  ÀÌÀç¿í(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 05-29 Room 3(3F) 15:40~16:10 [2020³â Çùµ¿¿¬±¸°úÁ¦] ±Ù°Å Áß½ÉÀÇ °í·É ¸¸¼ºÄáÆϺ´ ȯÀÚ Áø·áÁöħ: 3³âÂ÷ º¸°í  È«À¯¾Æ(´ëÀü°¡Å縯¼º¸ðº´¿ø) 
±³À°½Ã°£ 05-29 Room 3(3F) 16:10~16:40 [2020³â Çѱ¹º¸°ÇÀǷῬ±¸¿ø °úÁ¦/2021 Çùµ¿¿¬±¸°úÁ¦] ¸¸¼ºÄáÆϺ´ ȯÀÚ Åõ¼®¹æ¹ý ¼±ÅÃÀ» À§ÇÑ °øµ¿ÀÇ»ç°áÁ¤ ÀÓ»ó½ÃÇè (SDM-ART): 2³âÂ÷ º¸°í  ±è¼¼Áß(ºÐ´ç¼­¿ï´ëÇб³º´¿ø) 
±³À°½Ã°£ 05-29 Room 3(3F) 16:40~17:10 [2021³â Çùµ¿¿¬±¸°úÁ¦] ÀΰøÁö´É ±â¹Ý ÀÓ»ó-º´¸® ÅëÇÕ IgA ½ÅÀå¿° ¿¹ÈÄ ¿¹Ãø ¸ðµ¨ °³¹ß  ÀÌÇÏÁ¤(¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 05-29 Room 3(3F) 17:10~17:40 [2021³â Çѱ¹º¸°ÇÀǷῬ±¸¿ø °úÁ¦] A Pragmatic Randomized Clinical Trial: Twice vs Thrice Weekly Incident Hemodialysis in Elderly Patients (PRIDE)  ±Ç¼øÈ¿(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 05-29 Room 4(3F) 08:30~09:00 Impact of Intensive Blood Pressure Lowering on Cardiovascular and Renal Outcomes  ±èÇзÉ(¼­¿ïƯº°½Ãº¸¶ó¸Åº´¿ø) 
±³À°½Ã°£ 05-29 Room 4(3F) 09:00~09:30 Updated Guidelines on Blood Pressure Control in Patients With Kidney Diseases  ÇѽÂÇõ(¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 05-29 Room 4(3F) 09:30~10:00 Out-Of-Office Blood Pressure Corresponding to 120 mmHg in Intensive Blood Pressure Control  ¹Ú¼ºÇÏ(¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 05-29 Room 4(3F) 10:00~10:30 Masked Uncontrolled Hypertension in Chronic Kidney Disease in Intensive Blood Pressure Control  °íÀº½Ç(¿©Àǵµ¼º¸ðº´¿ø) 
±³À°½Ã°£ 05-29 Room 4(3F) 10:40~11:10 °©»ó¼±ÁúȯÀÇ Áø´Ü°ú Ä¡·áÀÇ ÃÖ½ÅÁö°ß  Á¶À±¿µ(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 05-29 Room 4(3F) 11:10~11:40 Primary Aldosteronism Áø´Ü°ú Ä¡·áÀÇ ÃÖ½ÅÁö°ß  ÀÓÁ¤¼ö(¿øÁÖ¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 05-29 Room 4(3F) 11:40~12:10 Dyslipidemia Treatment in Chronic Kidney Disease  À̼ҿµ(ºÐ´çÂ÷º´¿ø) 
±³À°½Ã°£ 05-29 Room 4(3F) 12:10~12:40 Osteoporosis Treatment in Chronic Kidney Disease  ±è±âÇ¥(ÀÎÇϴ뺴¿ø) 
±³À°½Ã°£ 05-29 Room 4(3F) 13:30~14:10 Åõ¼® ȯÀÚ¿¡¼­ ´Ü¹é ¼·Ãë¿Í ´Ü¹éÁú-¿­·® ¿µ¾ç½ÇÁ¶ (PEW)  À̼º¿ì(ÀÇÁ¤ºÎÀ»ÁöÀǴ뺴¿ø) 
±³À°½Ã°£ 05-29 Room 4(3F) 14:10~14:50 Åõ¼® ȯÀÚ¿¡¼­ ¿Ã¹Ù¸¥ ´Ü¹é ¼·Ãë  ±èÁö¿¬(ÀºÆò¼º¸ðº´¿ø) 
±³À°½Ã°£ 05-29 Room 4(3F) 14:50~15:30 ½Ã¿¬: Åõ¼® ȯÀÚ¿¡¼­ °Ç°­ÇÏ°Ô À߸Դ ½Ä»ç ¸¸µé±â  ±è¿ìÁ¤(°­³²¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 05-29 Room 4(3F) 14:50~15:30 ½Ã¿¬: Åõ¼® ȯÀÚ¿¡¼­ °Ç°­ÇÏ°Ô À߸Դ ½Ä»ç ¸¸µé±â  ÃÖÀºÁ¤(ÇѾç´ë) 
±³À°½Ã°£ 05-29 Room 4(3F) 08:30~08:40 Effect of Plasminogen Activator Inhibitor-1 (PAI-1) On Phenotype Transition of Human Peritoneal Mesothelial Cells (MCs)  ±è´Þ¾Æ(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 05-29 Room 4(3F) 08:40~08:50 Fasting Blood Glucose Level and All-Cause Mortality in Peritoneal Dialysis Patients  ±èÁ¾È£(°æÈñÀÇ´ë) 
±³À°½Ã°£ 05-29 Room 4(3F) 08:50~09:00 Synergy of Selective Inhibitor of PDE-5 and 5-HT2B Receptor: A Potent Anti-fibrotic Strategy for Abrogating Fibrotic Potential of Peritoneal Fibroblasts in PD Patients  Saurabh Chaturvedi(GSVM Medical College) 
±³À°½Ã°£ 05-29 Room 4(3F) 09:00~09:10 Cross-Talk Between Mesothelial Cells (MCs) And Adipocytes (ACs) As a Trigger for Peritoneal Fibrosis in Peritoneal Dialysis (PD)  °­ÇöÁ¤(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 05-29 Room 4(3F) 09:10~09:20 Combined Impact of Mean and Variability of Non-HDL-Cholesterol on Cardiovascular Risk in Patients Undergoing Hemodialysis  ÀÌÇѺñ(¼­¿ï¼º¸ðº´¿ø) 
±³À°½Ã°£ 05-29 Room 4(3F) 09:20~09:30 Circulating Follistatin-like protein-1 Levels Predicts the Risk of Cardiovascular Events and Death in Hemodialysis Patients  ±è´ë±Ô(°­µ¿°æÈñ´ëº´¿ø) 
±³À°½Ã°£ 05-29 Room 4(3F) 09:30~09:40 Elevated Serum Alkaline Phosphatase Levels and Risk of All-Cause Mortality in Dialysis Patients  Md Salman Hussain(Jamia Hamdard) 
±³À°½Ã°£ 05-29 Room 4(3F) 09:40~09:50 A Risk Prediction for Early-Peak Mortality in Korean Elderly Hemodialysis Patients: Data From a Multicenter Cohort Study  ¹Ú¿ì¿µ(°è¸íÀÇ´ë ½ÅÀå³»°ú) 
±³À°½Ã°£ 05-29 Room 4(3F) 09:50~10:00 Fasting Blood Glucose Level and All-Cause Mortality in Hemodialysis Patients  À±¼ö¿µ(°æÈñÀÇ´ë) 
±³À°½Ã°£ 05-29 Room 4(3F) 10:00~10:10 Femoral Vein Tunnelled-cuffed Catheters in a Single Tertiary Teaching Hospital: A Five Years Retrospective Study in Malaysia  Suek Xuan Pon(University Malaya) 
±³À°½Ã°£ 05-29 Room 4(3F) 10:10~10:20 Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response After Heterologous Immunizations With ChAdOx1/BNT162b2 in End-Stage Renal Disease Patients on Hemodialysis  ±è´ë±Ô(°­µ¿°æÈñ´ëº´¿ø) 
±³À°½Ã°£ 05-29 Room 4(3F) 10:20~10:30 Strict Blood Pressure Control Was Associated With Better Survival in Korean Hemodialysis Patients, but Not in Peritoneal Dialysis  ÀÌÁÖ°æ(°í·ÁÀǴ뱸·Îº´¿ø) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽÅÀåÇÐȸ KSN(Korea Society of Nephrology) 2022 (4ÀÏÂ÷) : 2022-05-29""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ½É½Å¾ÈÁ¤°ú ¿ì¿ï°¨ °ü¸®¸¦ À§ÇÑ À½¾Ç Ä¡·áÀÇ È¿°ú – Mozart Effect and Brain Power : 2022-05-30
´ÙÀ½±Û (¿Â¶óÀÎ) 2022³âµµ °æ»óºÏµµÀÇ»çȸ Á¾ÇÕÇмú´ëȸ(2ÀÏÂ÷) : 2022-05-29
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20467 ¼­¿ï 2024 ´ëÇÑÇ÷¾×ÇÐȸ Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-31 [1] 0 15 2024-04-17
20466 °æ±â ¾ÆÁִ뺴¿ø ÀÀ±ÞÀÇÇаú ¼³¸³ 30Áֳ⠱â³ä ½ÉÆ÷Áö¿ò : 2024-05-30 [1] 0 5 2024-04-17
20465 ¼­¿ï Á¦20Â÷ ´ëÇѸð¹ßÇÐȸ Çмú´ëȸ ÇÁ·Î±×·¥ : 2024-05-26 0 10 2024-04-17
20464 °æ±â 2024³â Á¦86Â÷ ´ëÇÑ»ý½ÄÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-26 0 5 2024-04-17
20463 ¼­¿ï 2024³â ´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸ Ãá°è ½ÉÆ÷Áö¾ö : 2024-05-26 0 4 2024-04-17
20462 ¼­¿ï ´ëÇÑÃæ°ÝÆÄÄ¡·áÇÐȸ 2024 Ãá°è Çмú´ëȸ : 2024-05-26 0 7 2024-04-17
20461 ¼­¿ï Áø´Ü ü°èÀû¹®Çå°íÂû ¿öÅ©¼¥ : 2024-05-25 0 11 2024-04-17
20460 ¼­¿ï ´ëÇѺñ¸¸ÇÐȸ Á¦17ȸ ODOT (One Day Course of Obesity Treatment) : 2024-05-25 0 7 2024-04-17
20459 ¼­¿ï 2024³â Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2024-05-24 0 3 2024-04-17
20458 ¼­¿ï 2024 Á¦12ȸ ´ëÇÑÇ÷¾×ÇÐȸ Ç÷¿ìº´¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-24 0 8 2024-04-17
20457 ¼­¿ï 2024³â ¿µµîÆ÷±¸ÀÇ»çȸ Ãá°è Çмú´ëȸ : 2024-05-21 0 7 2024-04-17
20456 ¼­¿ï 2024³â ´ëÇÑÀÓ»ó°Ç°­ÁõÁøÇÐȸ Ãá°èÇмú´ëȸ ¹× ¿¬¼ö°­Á : 2024-05-19 0 8 2024-04-17
20455 ¼­¿ï Á¦7Â÷ ´ëÇѼö¸éÈ£ÈíÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-19 0 3 2024-04-17
20454 ¼­¿ï 2024 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ãá°è¿¬¼ö°­Á : 2024-05-18 0 5 2024-04-17
20453 ¼­¿ï 2024³â ´ëÇÑ¿¬ÇÏÀå¾ÖÇÐȸ Á¦14ȸ Ãá°èÇмú´ëȸ : 2024-05-18 0 3 2024-04-17
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷